Related Experiment Video
Updated: May 5, 2026
10:05
Testing the Efficacy of Pharmacological Agents in a Pericardial Target Delivery Model in the Swine
Published on: July 7, 2016
7.9K
Clinical efficacy of xamoterol, a beta 1-adrenoceptor partial agonist, in mild to moderate heart failure. U.K.
D G Waller1, J Webster, C A Sykes
1Clinical Pharmacology Group, Southhampton General Hospital, U.K.
European Heart Journal
|November 1, 1989
Summary
Xamoterol, an alpha beta 1-adrenoceptor partial agonist, improved exercise duration and reduced breathlessness in patients with mild to moderate heart failure. This study highlights xamoterol
Area of Science:
- Cardiology
- Pharmacology
Background:
- Heart failure is a significant cardiovascular condition affecting millions worldwide.
- Current treatments aim to manage symptoms and improve quality of life.
Purpose of the Study:
- To evaluate the clinical efficacy of xamoterol, an alpha beta 1-adrenoceptor partial agonist, in patients with mild to moderate heart failure.
- To assess the effects of xamoterol on exercise capacity and subjective symptoms.
Main Methods:
- A multicentre, double-blind, randomized, parallel-group study.
- 240 patients with mild to moderate heart failure were enrolled.
- Patients received either xamoterol or placebo for 3 months after a 1-week placebo run-in.
Main Results:
- Mean exercise duration increased by 19% with xamoterol versus 7% with placebo.
- Xamoterol significantly reduced peak exercise heart rate.
- Subjective improvement in breathlessness was observed with xamoterol, but not fatigue.
Conclusions:
- Xamoterol demonstrates sustained improvement in symptoms and exercise duration in mild to moderate heart failure.
- Xamoterol is a potential therapeutic option for managing heart failure.
Related Concept Videos
01:30Adrenergic Agonists: Therapeutic Uses
2.0K
Adrenergic agonists have diverse therapeutic uses across various medical conditions and emergencies.
Emergency and Intensive Care Unit (ICU) applications: Pressor agents increase blood pressure, heart rate, and contractility in shock and organ failure situations. Dopamine can induce vasodilation and stimulate adrenoceptors. Endogenous catecholamines are effective in treating cardiogenic shock. α2-agonists like clonidine can reverse anesthesia-induced hypertension.
Allergies and...
Emergency and Intensive Care Unit (ICU) applications: Pressor agents increase blood pressure, heart rate, and contractility in shock and organ failure situations. Dopamine can induce vasodilation and stimulate adrenoceptors. Endogenous catecholamines are effective in treating cardiogenic shock. α2-agonists like clonidine can reverse anesthesia-induced hypertension.
Allergies and...
2.0K
01:27Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers
1.8K
β-receptor blockers significantly impact the cardiovascular system by counteracting catecholamine-induced sympathetic responses. These medications decrease heart rate, contractility, and cardiac output, potentially leading to cardiac depression, life-threatening bradycardia, and death. Therapeutically, β-blockers function as mild antihypertensives and are utilized in treating angina pectoris and cardiac arrhythmias. However, nonselective β-blockers inhibit β2-receptors in...
1.8K
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
2.1K
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
2.1K
01:22Heart Failure Drugs: β-Blockers
2.9K
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
2.9K
01:25Antiasthma Drugs: β2-Adrenoceptor Agonists
2.1K
Bronchodilators are critical in managing asthma, a chronic respiratory condition characterized by airway constriction due to inflammation and hyper-reactivity. Specifically, bronchodilators ease this constriction by relaxing the bronchial muscles, facilitating easier breathing.
One class of bronchodilators includes β2-adrenoceptor agonists. These agents target the β2-adrenoceptors located on bronchial smooth muscle cells. By stimulating these receptors, β2-agonists induce...
One class of bronchodilators includes β2-adrenoceptor agonists. These agents target the β2-adrenoceptors located on bronchial smooth muscle cells. By stimulating these receptors, β2-agonists induce...
2.1K
01:30Heart Failure V: Medical Management
641
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
641